International Association of
Therapeutic Drug Monitoring and Clinical Toxicology
Fostering education, research and practice in TDM and CT

TDM in Oncology

Gareth Veal

Chair

Gareth Veal
Newcastle upon Tyne, UK

contactus273x169

Contact Us
Scientific Committees
TDM in Oncology Committee

D.J.A.R. Moes

Vice-Chair

D.J.A.R. Moes
Leiden University Medical Center, The Netherlands

Background & Purpose of the Committee

  • Creating and promoting awareness of the need for TDM in cancer therapy,
  • Stimulating studies which demonstratethe utility in improving patient outcomes,
  • Education of the IATDMCT members on advances and opportunities in the area,
  • Education of medical oncologists and regulatory authorities of the importance of TDM in oncology,
  • Development of consensus guidelines for implementation in oncology.

Scope of the Oncology Committee is:

  • TDM for cancer treatment in hematology and oncology,
  • Chemotherapy, molecular targeting therapy, hormonal therapy and immunotherapy,
  • Topics relating to drug concentrations in blood, pharmacogenomics and other biomarkers for the benefit of precision medicine.

Activities Planned/Committee Initiatives Currently in Progress

  • Consensus guideline document for TDM of busulfan
  • Consensus guideline document for TDM of imatinib
  • Consensus guideline document for TDM of paclitaxel
  • Support for future IATDMCT meeting workshops and symposia

Past Years' Activities Held/Committee Initiatives

  • Publication of consensus guideline document for TDM of Imatinib
  • Support for Rome meeting with workshops and symposia